Registration successful
Account activated – pending validation.
Your account has been activated successfully, but we still need to validate you as a healthcare professional. We’ll send you an email with the result of the validation process in the next [five] days.
In the meantime, you can enjoy access to all the latest news, events and resources on our website
Efficacy in focal epilepsy
How efficacious is Keppra as an adjunct?
Guideline recommendations
Levetiracetam is recommended by guidelines as a first-line monotherapy in adult patients with focal epilepsy1-4
Guideline recommendations on the use of levetiracetam
National Institute for Health and Care Excellence 2020 update1
Statements are paraphrased. For further details, please refer to full document.
International League Against Epilepsy 20132
Statements are paraphrased. For further details, please refer to full document.
Scottish Intercollegiate Guidelines Network 20153
Statements are paraphrased. For further details, please refer to full document.
American Epilepsy Society 20184
Statements are paraphrased. For further details, please refer to full document.
Read more about Keppra
Abbreviations
AED: anti-epileptic drug; AES: American Epilepsy Society; FDA: Food and Drug Administration (US); ILAE: International League Against Epilepsy; NICE: National Institute for Health and Care Excellence; RCT: randomised controlled trial; Rx: prescription; SIGN: Scottish Intercollegiate Guidelines Network.
References
- NICE Guidelines (2020 update). Available at: https://www.nice.org.uk/guidance/cg137. Accessed April 2020.
- Glauser T, et al. Epilepsia 2013;54(3):551–563.
- SIGN 143. Diagnosis and management of epilepsy in adults: May, 2015. Available at: https://www.sign.ac.uk/sign-143-diagnosis-and-management-of-epilepsy-in-adults.html. Accessed April 2020.
- Kanner AM, et al. Neurology 2018;91(2):74–81.
Trade marks are owned by or licensed to the GSK group of companies.
PM-MY-LVT-WCNT-200007 01/21
